Ana səhifə

Rajiv gandhi university of health sciences bangalore, karnataka


Yüklə 285 Kb.
tarix27.06.2016
ölçüsü285 Kb.
Cardioprotective activity of Matricaria recutita Linn on Sprague-Dawley rats
Protocol of Dissertation Submitted
By
Mr. NIRAV M. PATEL

To
RAJIV GANDHI UNIVERSITY OF HEALTH SCIENCES

BANGALORE, KARNATAKA.



Under the guidance of
Dr. I S MUCHANDI

Professor

(2008-2009)

Department of Pharmacology,

HANAGAL SHRI KUMARESHWAR COLLEGE OF PHARMACY,

BAGALKOT- 587101, KARNATAKA


RAJIV GANDHI UNIVERSITY OF HEALTH SCIENCES
KARNATAKA-BANGALORE
ANNEXURE II
PROFORMA FOR REGISTRATION OF SUBJECTS FOR
DISSERATATION




1.

Name of the Candidate and Address



NIRAV M. PATEL

DEPARTMENT OF PHARMACOLOGY,

H.S.K.COLLEGE OF PHARMACY,

B.V.V.S. CAMPUS,

BAGALKOT-587101. KARNATAKA


2.

Name of the Institution



H.S.K.COLLEGE OF PHARMACY,

B.V.V.S.CAMPUS,

BAGALKOT-587101. KARNATAKA


3.

Course of Study and Subject




MASTER OF PHARMACY IN

PHARMACOLOGY


4.

Date of Admission to Course




16 / 07/ 2008


5.

Title of the topic:

“Cardioprotective activity of Matricaria recutita Linn. in Sprague- Dawley rats”





6.

Brief resume of the intended work


    1. Need for the study:

Cardiovascular disease (CVD) is the most relevant serious disorder in the developed nation. The American Heart Association as report that in 2002, 62 million American, 32 million male and 30 million female and preliminary mortality data from 2005 show that CVD accounted 861,826 of all 2447,910 deaths in 2005 in United States. This is 35.2 % percent of all deaths around the global had a cardiovascular disease including hypertension, so discharge from various survey report from hospital, cardiovascular disease have been rising statistically now exceed 6 million per year1-2. Ischemic heart disease is caused primarily by coronary atherosclerosis, and result in an imbalance between oxygen supply and demand with resulting ischemia3. Cardiovascular disease claimed 949,619 lives, or 1 of every 2-5 deaths, in United States in 1998. Coronary artery disease was responsible for 459,841 deaths from CVD4. Heart failure is resulting any disorder that impairs the ability of the ventricle to fill with or eject blood, thus rendering the heart unable to pump blood at a rate sufficient to demands of the body5. Approximately 5 million American have heart failure, with an additional 550,000 cases diagnosed per year6. Complications of Congenital Heart Disease are myocardial hypertrophy and other changes of cardial remodeling brought about by the congenital defect7. Rupture of the intraventricular septum is an uncommon and often fatal complication of myocardial infarction8. Chamomile prepared as a tea used in most of country and chamomile containing active constituent apigenin and other flavonoids. Apigenin alone used in several cardiovascular diseases and which was proved by scientifically. But chamomile plant extract scientific validation as a cardioprotective was not carried out, especially in Ischemic-reperfusion injury models9. In view of this, the present study was designed to evaluation of cardioprotective activity of Matricaria recutita Linn. in Isoproterenol-induced myocardial infarction and ischemic-reperfusion injury in isolated heart models.




6.2 Review of literature:

Plant profile:

Title of plant : Matricaria recutita Linn.

Family : Asteraceae (Compositae)

Synonyms : Matricaria, German chamomile, Sweet false chamomile.s

Matricaria recutita Linn. (Chamomile) has been used medicinally for thousands of year, and is widely used in Europe. It is a popular treatment for numerous ailments, including sleep disorders, anxiety, digestion , intestinal conditions, skin infections, inflammation (including eczema), wound healing, infantile colic, teething pains and diaper rash. In the United States, Chamomile is best known as an ingredient in herbal tea preparations advertised for mild sedative effects10. German chamomile contains terpenoids, flavonoids, coumarins, other constituents such as tannin, polysaccharide and choline. Chamomile used externally for wounds, ulcers, ecezema, gout, neuralgia, rheumatic pain, hemorrhoids, leg ulcers11. Anxiolytic effect of Matricaria recutita Linn. flowers and branch lets were studied in mice12 .

Pharmacological actions:

Recently it has been showed to posses Antioxidant13, Diabetic complication14, Cardiac effects15 , Anti microbial activity16, Anti proliferative and apoptic effects17. Cardiovascular effects as increase atrial rate, relaxed thoracic aorta, hemodynamic effects 18,19,20 and anti-ulcer activity21. Chamomile’s main active constituents are apigenin and bisabolol. Apigenin having cardioprotective activity9.

6.3 Objectives of the study:

The traditional practitioners well known Matricaria recutita Linn. will be extracted by using polar and non polar solvents and these extracts will be used for its cardioprotective properties using Isopro- terenol induced myocardial infarction and Ischemic-reperfusion injury in isolated rat heart models.

.



7.

The objective of the study:-


  1. Cardioprotective potential of Matricaria recutita L. by measuring hemodynamic parameters like Blood pressure, Systolic blood pressure, Mean arterial pressure in ISO-induced myocardial necrosis in rats.

  2. Cardioprotective activity of Matricaria recutita L. by measuring Biochemical, Myocardial injury markers and Histopathological studies in ISO-induced myocardial necrosis in rats.

  3. Cardioprotective potential of Matricaria recutita L. by measuring hemodynamic parameters like Blood pressure, Systolic blood pressure, Mean arterial pressure in Ischemia-reperfusion induced myocardial damage in isolated rat heart preparation.

  4. Cardioprotective activity of Matricaria recutita L. by measuring Biochemical, Myocardial injury markers and Histopathological studies in Ischemia-reperfusion induced myocardial damage in isolated rat heart preparation.

Methods and materials:

7.1 Source of data:

The data will be collected from animal experiments and standard parameters for the study. The selection of doses 100, 200 and 300 mg/kg of body weight will be based on earlier literature22.

7.2 Materials :

Materials : Matricaria recutita linn.

Animals : Either sex (4 to 8 weeks), Sprague-Dawley rats.

Chemicals : All chemicals will be used analytical research grade.

Instruments : Spectrophotometer, Langendroff’s assembly, Refrigerator Centrifuge, Biopac (NIBP),

Tissue homogenizer, INCO-ECG, and enzyme kits.







Animals were subdivided into twelve containing Eight animals in each groups.

Group-I : Effect of vehicle on normal control group.

Group II : Effects of vehicle on ISO-induced myocardial damage.

Group-III : Effect of standard drug on ISO-induced myocardial damage.

Group-IV : Effect of 100 mg/kg of extract on ISO-induced myocardial damage.


Group-V : Effect of 200 mg/kg of extract on ISO-induced myocardial damage.

Group-VI : Effect of 300 mg/kg of extract on ISO-induced myocardial damage.

Group-VII : Effect of vehicle on normal control group.


Group-VIII : Effect of vehicle on Ischemia-reperfusion induced injury in isolated heart.

Group-IX : Effect of standard drug on Ischemia-reperfusion induced injury in isolated heart.

Group-X : Effect of 100 mg/kg of extract on Ischemia-reperfusion induced injury in isolated heart.

Group-XI : Effect of 200 mg/kg of extract on Ischemia-reperfusion induced injury in isolated heart.

Group-XII : Effect of 300 mg/kg of extract on Ischemia-reperfusion induced injury in isolated heart.

7.3 Methods:

7.3.1 Isoproterenol (ISO) induced Myocardial necrosis:

Treatment protocol

The animals were divided into six groups. The first group, treated with normal Saline ( Normal control group), the second group received ISO and third, fourth, fifth and sixth groups received

Standard drug, 100, 200, 300 mg/kg of body weight dose of methanolic extract Matricaria recutita L. was given to each animal orally for 12 days and ISO administrated subcutaneously on 11th and 12th day. The animals were sacrificed 24 h after the second dose of ISO, under chloroform anesthesia.




Heart were removed and processed immediately for morphological and histopathological studies. The heart were homogenated ice cold buffer and used for biochemical estimation23.




Determination of myocardial necrosis by direct staining:

Myocardiaum of rat was frozen immediately after removal. When the tissue was firm, the heart was sliced into 1 mm section and incubated at 370 C for 20 min. in 1% TTC stain. The formazan precipitate resulting from the reaction of Lactate dehyrogenase in normal and ischemic region delineated the area at risk from the infracted tissue24.



7.3.2 Ischemia-reperfusion induced injury in isolated heart:

A Langendroff apparatus for the isolated perfused heart was set up as mentioned elsewhere25. The heart was isolated from each animal 2 hrs after the last dose of the drug(s) under ketamine ( 70 mg/kg) and xylazine ( 10 mg/kg, i.p.) anesthesia. The isolated heart was perfused with Kreb-Henseleit (K-H) solu-



tion gassed with carbogrn ( 95 % 02 and 5 % CO2) at 370 C at a constant flow rate of 5 ml/min. The composition of K-H solution was (mM) NaCl 118, KCL 4.7,NaHCO3 25, NaHPO4 1.0, MgSO4.7H2O 0.57, CaCI2 2.5 and glucose 11. The pH of K-H solution was adjusted to 7.4 to avoid K-H buffer acidosis that may occur after prolonged gassing with carbogen. The heart was allowed to equilibrate for 10 min and then regular recording were taken for a perfusion period of 15 min. Measurement of contractile force was done using force displacement transducer and recorded on a student Physiograph (INCO, Mumbai, India). After the initial preischemic perfusion, heart was subjected to 15 min of global no-flow ischemia26 by blocking the flow of K-H solution and carbogen supply followed by 15 min of reperfusion. The heart rate and developed tension were measured during preischemic and post-ischemic period and recovery (%) was calculated. Volume fraction of interstitial space (VFITS) in myocardial tissue was determined from hematoxylin and eosin (H &E) stained transverse section by using the equation27.




VFITS = (100 % X Area of interstitial space) / Total tissue area.

The biochemical estimation: The biological activities of LDH28, CK-MB were evaluated in coronary effluent (perfusate) during pre and post ischemic period as well as 10 % heart tissue homogenate for enzyme levels like SOD29, Catalase, GSH30 and Total protein were estimated31,32.

Histopathological examination: Two animals from each will be sacrificed on the day of blood withdrawal and heart will be isolated and tissue will be immersed in 10 % formalin solution for histopathological studies. Sample will be emended in paraffin sectioned and stained with haemotoxolin and eosin33 .

Statistical analysis: All the data were expressed in mean ± SEM. The significance of differences in mean between control and treated animals for different parameters determined by one way using ANOVA followed by Tukey multiple comparison test. Significance for difference between groups were evaluated for student’s t-test to come to final conclusion.

    1. Dose the study require any investigations or interventions to be conducted on patients or

other humans/animals? If so please describe briefly

Yes, the above study requires to be carried out in Rats. So for this study albino rats will be used.

    1. Has ethical clearance been obtained from your institution in case of 7.3?



Yes, study of cleared from institutional ethical committee and copy enclosed with the protocol.






8.


References :


  1. Eugene Braunwald. Disorders of cardiovascular system, Principle of Internal Medicine, edn 16th, Volume-II, McGraw-Hiil, Medical Publishing division; 2005:1301.


2. Wayne Rosamond., Katherine Flegal., Kurt Greenlund., Steven Kittner. A report from the

American Heart Association Committee and stroke statistics sub committee. Heart Disease and

Stroke Statistics-2008:e26.
3. Joseph T., DiPiro., Robert L. Ischemic Heart Disease, Pharmacotherapy. A Pathophysiological

Approach, 6th edn, Talbert;1999:261.


4. American Heart Association. 2001 Heart and Stroke Statistical Update.Dallas,AHA 2000:1-33.
5. Hunt S.A., Baker D.W., Chin M.H. ACC/AHA Guideline for the evaluation and management

of chronic heart failure in the adult: Executive summary. A report of the American College

of Cardiology/American Heart Association Task Force on Practice Guideline (Committee to

Revise the 1995 Guideline for the Evaluation and Management of heart Failure): Developed in

Collaboration with International Society for Heart and Lung Transplantation; endorsed by the

Heart Failure Society of America. Circulation 2001;104:2996-3007.


6. American Heart Association.2004 Heart and Stroke Statistical Update. Dallas, AHA 2003.
7. Robbins., Cortan. Pathological Basis of Disease by Kumar- Abbas- Fausto, 7th edn, Elsevier,

12:564.
8. Szkutnik M., Kusa J., Bialkowskl J . The use of two Amplatzer “ Cribriform ” Septal Occluders

to close matiple postintaction ventricular septal defects. Text Heart Inst J 2008;35:362-4.

  1. Ko F.N., Huang T.F., Teng C.M. Vasodilatory action mechanisms of apigenin isolated from

Apium graveolens in rat thoracic arota. Biochem Biophy Acta 1991;1115:69-74.



10. Glowania H.J., Raulin C., Swoboda M. Effect of Chamomile on wound healing –A Clinical

double-blind study. Z. Hautkr 1987; 62 (17):1262,1267-1271.







11. Newall C.A., Anderson L.A., Phillipson J.D. Herbal medicines . A guide for health-care profes-

sionals. London, Pharmaceutical press 1996;9: 296.


12 . Avallone R., Zanoli P., Corsi L., Cannazza G., Baraldi M. Benzodiazepine-like compounds

and GABA in flower heads of Matricaria chamomilla. Phytother Res 1996;10:S177-179.



13. Pereira R.P., Fachinetto R., de Souza Prestes A., Puntel R.L., Santos da Silva G.N., Heinzmann

B.M., Burger M.E., Morel A.F., Morsch V.M., Rocha J.B. Antioxidant Effects of Different

Extracts from Melissa officinalis, Matricaria recutita and Cymbopogon citratus. Neurochem

Res 2008.



14. Kato A. , Minoshima Y., Yamamoto J., Adachi I., Watson A.A., Nash R. J. Protective effects of

dietary Chamomile tea on diabetic complication. J Agric Food chem 2008;56 (17):8206-11.



15. Lawrence Gould, Rmana Reddy C.V., Robert F. Gomorecht. Cardial Efects of Chamomile

Tea. J Clin Pharmacol 1973;13:475.



16. Noqueira J.C., Diniz Mde F., Lima E.O. Anti microbial activity of plants in Acute Otiti Externa.

Braz J Otorhinolarygol 2008 ;74(1):118-24.




  1. Srivastava J.K., Gupta S. Antiprliferative and apoptic effects of chamomile extract in various

human cancer cells. J Agric Food Chem 2007;55 (23): 9470-8.




  1. Lorenzo P.S., Rubio M.C., Medina J.H., Alder-Graschinsky E. Involvement of monoamine

Oxidase and noradrenaline uptake in the positive chronotropic effects of apigenin in rat atria.

Euro J Pharmacol 1996; 312:203-7.

19. Ko F.N., Huang T.F., Teng C.M. Vasodilatory action mechanisms of apigenin isolated from

Apium graveollens in rat thoracic arota. Biochem Biophy Acta 1991; 1115:69-74.

20. Gould L, Reddy C.V.R., Gomprecht R.F. Cardiac effects of chamomile tea. J Clin Pharmacol

New Drugs 1973; 13:475-479.




21. Tamasdon S., Cristea E., Mihele D. Action upon gastric secretion of Rbiniae flores, chamomillae

flores and strobuli lupuli extracts. Farmacia 1981; 29:71-75.










22. Ajay Kumar Gupta., Havagiray Chitme., Sujata K.D., Neelam Misra. Antioxidant activity of

Chamomile recutita capituta, Methamolic Extracts against CCl4 - Induced Liver Injury in Rats,

J Pharmacol Toxi 2005:1-7.


23. Meen Sharma., Kamal Kishore., Suresh K. Gupta., Sujata Joshi., Dharamvir S. Arya. Cardio-

Protective pontetial of Ocimum sanctum in isopreterenol induced myocardial infarction in rats,


Mol Cellular Biochem 2001;225:75-83.

24. Lie J.T., Pairolero P.C., Holley K.E..Macroscopic enzyme mapping verification of large, homo-

genous, experimental myocardial infarcts of predictable size and location in dogs. J Thorac

Cardiovasc Sug 1957;69:599-605.




25. Inamder M.N., Venkarataraman B.V., Aleem M.A. A simple and improved perfusion apparatus

for isolated hearts. Ind J Pharmacol 1994;26:262-265.




26. Mouhieddine S., Tresallet N., Boucher F., Leiris J.D. Ultrastructural basis of the free-radical

scavering effects of Indapamide in experimental myocardial ischemia and reperfusion. Cardio-

vasc Pharmacol 1993;22:S47-52.



27. Zhai P., Eurell T.E., Cottaus R., Jeffery E.H., Bahr J.M., Gross D.R.. Effect of oestrogen on

global myocardial ischemia reperfusion injury in female rats. Am J Physiol Heart Circle 2000;


279:H2766-H2775.



28. Cabaud P.G., Wroblewski F. Colorimetric measurement of lactic dehyrogenase activity of body

fluid. Am J Clin Path 1958;30: 234-236.



29. Ellman G.L. Tissue sulfhydry groups. Arch Biochem Biophys 1959:82:70-77.




30. McCord J.M., Fridovich I. Superoxide dismutase: An enzyme fuction for erythrocuprcin ( hemo-

cuprcin). J Biol Chem 1969;244:6049-6055.



31. Erich F., Elastner M. Inhibition of nitrite formation from hyroxy ammonium chloride. A simple

assay of super oxide dismutase. Analy Chem 1976; 70: 616-20.









32. Eva M.L. Mechanism of pH dependent hydrogen peroxide cytotoxicity in-vitro. Arch Biochem

Biophys 1988;365:362-72.




33. Carbonell L.F., Salazai F.J., Garcia Estan J., Ubeda M., Quesada T. Normal homodynamic

parameters in conscious rats, Rev Exp Physiol 1985;41:437-442.







9.


SIGNATURE OF CANDIDATE




( NIRAV M. PATEL)


10.


REMARKS OF THE GUIDE



The details literature study indicate that LDH, CD-MK, and Biochemical parameter estimation are important due to release of ROS during ischemia-reperfusion injury. In our presence study the plant based medicine may explore the opportunity for drug treatment and curing of cardiovascular disease or cardioprotective activity.



11.



NAME AND DESIGNATION OF

THE GUIDE



Dr. I.S. MUCHANDI

Principal and professor





12.


SIGNATURE





13.


CO-GUIDE





14.


SIGNATURE




15.


HEAD OF THE DEPARTMENT


Prof. I.S.MUCHANDI

H.O.D. , Department of Pharmacology

H.S.K.College of Pharmacy,

B.V.V.S. Campus, Bagalkot-587101.




16.


SIGNATURE




17.


REMARKS OF THE PRINCIPAL

The above mentioned information is correct and I recommended the same for approval.





18.


NAME OF THE PRINCIPAL


Prof. I.S.MUCHANDI

H.O.D., Department of Pharmacology

H.S.K.College of Pharmacy,

B.V.V.S. Campus, Bagalkot-587101.




19.


SIGNATURE







OFFICE OF THE INSTITUTIONAL ANIMAL ETHICS COMMITTEE (IAEC)

HANAGAL SHRI KUMARESHWAR COLLEGE OF PHARMACY,

BAGALKOT-587101, KARNATAKA
REG NO.821/01/a/CPCSEA, Dated: 6th AUG 2004 UNDER THE RULES 5(a) OF THE

“BREEDING OF AND EXPERIMENTS ON ANIMALS (Control and Supervision)

RULES 1998”

Ref: HSKCP/IAEC, Clear / 2008-09/1-8




CERTIFICATE

This is to certify that Mr. NIRAV M. PATEL a student of first M.Pharm is permitted to carry out experiments on animals for the dissertation / thesis work entitled as “Cardioprotective activity of Matricaria recutita Linn. in Sprague-Dawley rats as per details mentioned and after observing the usual formalities laid down by IAEC as per provision made by CPCSEA.



Animal house in charge CHAIRMAN

Form B

See rule [6 (a) and 8(a)]
PART A



(1)

Name and address of the Establishment:




H.S.K. COLLAGE OF PHARMACY

BAGALKOT, KARNATAKA.



(2)

Date and Registration Number of the Establishment:


821/01/a CPCSEA

(3)

Name, address and Registration NO. of the

breeder from whom acquired and the date of

acquisition:


OFFICE OF CPCSEA,

MINISTRY OF ENVIROMENT AND FOREST, 3rd SEAWARD ROAD, VALMIKINAGAR,THRIRUVANMIYUR,

CHENNAI-600041.



(4)

Place where the animals are presently kept:



ANIMAL HOUSE

H.S.K. COLLAGE OF PHARMACY

BAGALKOT, KARNATAKA.



(5)

Place where the experiment is to be performed:



DEPARTMENT OF PHARMACOLOGY

H.S.K. COLLAGE OF PHARMACY

BAGALKOT, KARNATAKA.


(6)

The date on which the experiment is to commence and the duration of the experiment:

15 MAY 2009


The protocol form for the research proposal - PART B in the case of experiments using other than non-human primate animals for ongoing/new projects, PART C for use of non-human primates for new projects and PART D for use of non-human primate for extension of ongoing projects – should be duly filled, singed and annexed with this form.

Signature
Dated: (Name and Designation)
Place:



PART – B
Protocol form for Research Proposal to be submitted to the

Committee on use of small animals / Animals other than non human



Primate in Biomedical Research for ONGOING / NEW PROJECTS



1.

Project Title :



Cardioprotective activity of Matricaria recutita Linn on Sprague-Dawley rats.


2.

Investigation (s) :

Designation


Dr. I.S. MUCHANDI

Principal and professor



3.

Department (s) :



DEPARTMENT OF PHARMACOLOGY

H.S.K. COLLAGE OF PHARMACY

BAGALKOT, KARNATAKA.



4.

(a) Funding Source (s): if any




----


(b) Are sufficient funds available for purchase and maintenance of the animals

----


©


Duration of present project :





  1. Number of months :




6 months

  1. Date of start of the Project :

(Experiment)


15 May 2009

  1. Date of termination of the project :




30 Oct 2009


5.


Date by which approval is needed in case the project is to be funded by outside agency (If less than six weeks from the date of admission, please justify below).




----






6.

Summary of project briefly summarize in laymen’s term the background, the objective and the experiment approach.





  1. Background:




Enclosed

  1. Objectives




Enclosed

(c) Experimental procedure:


Enclosed




7.

(a) Name of species


Sprague-Dawley rats.

Age


Sex

Weight

4-8 weeks

Either sex


200-250 g


(b)


Rationale for selection




Approximate number of animals required during the

first 12 months.




96

Justification of number (define treatment group and
number per group)



Six groups, Each group containing eight animals.

Number of animals housed per weeks






8.

List all invasive Non Surgical Animal Procedures and Potentially Stressful Noninvasive procedures to be used (Example IM injection, foot pad injection , venapunctures).




Invasive Non-surgical animal procedures.

Procedure and Approximate Frequency:


Enclosed






9.

10.

11.

Anesthetic and/or Analgesic and Dosage:


Ketamine hydrochloride, 140 mg/kg, given I.P. route.

Test substance injected and/or applied:


Test substance will administer Orally.


Does the protocol prohibit the use of anesthetic and analgesic for the conduct of painful procedures?
No.


With surgical procedure/Experimental procedure be performed?
No.


(a) Will the animal be sacrificed after surgery?
No.


(b) Give anticipated post operative survival time:
----


Will hazardous agent such as radioisotopes, carcinogens, radiation exposure, microbial and parasitic agent be administered to animals?
No



INVESTIGATOR SIGNATURE



DATE: ____________________







Verilənlər bazası müəlliflik hüququ ilə müdafiə olunur ©atelim.com 2016
rəhbərliyinə müraciət